Show simple item record

dc.contributor.authorKent, Sen_US
dc.contributor.authorHaynes, Ren_US
dc.contributor.authorHopewell, JCen_US
dc.contributor.authorParish, Sen_US
dc.contributor.authorGray, Aen_US
dc.contributor.authorLandray, MJen_US
dc.contributor.authorCollins, Ren_US
dc.contributor.authorArmitage, Jen_US
dc.contributor.authorMihaylova, Ben_US
dc.contributor.authorGrp, H-TCen_US
dc.date.accessioned2018-11-16T10:16:39Z
dc.date.available2016-04-20en_US
dc.date.issued2016-07en_US
dc.date.submitted2018-05-31T11:34:14.173Z
dc.identifier.issn1941-7705en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/51205
dc.description.sponsorshipHPS2-THRIVE was supported by grants from Merck (manufacturer of ER niacin–laropiprant, simvastatin, and ezetimibe), the UK Medical Research Council (A310), the British Heart Foundation (CH/1996001/9454), and Cancer Research UK (C500/A16896) (to the University of Oxford), and by a fellowship from the British Heart Foundation (FS/14/55/30806, to Dr Hopewell)en_US
dc.format.extent348 - +en_US
dc.relation.ispartofCIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMESen_US
dc.subjectcardiovascular diseaseen_US
dc.subjectclinical trialen_US
dc.subjecthospital costsen_US
dc.subjectniacinen_US
dc.subjectquality of lifeen_US
dc.titleEffects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costsen_US
dc.typeArticle
dc.rights.holder© 2016 American Heart Association, Inc.
dc.identifier.doi10.1161/CIRCOUTCOMES.115.002592en_US
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380609700003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume9en_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record